Quick Answer ACTUATE THERAPEUTICS, INC. reported R&D Expense of $10.29 million for fiscal year 2025. ACTUATE THERAPEUTICS, INC. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $10.29M -44.9% 2024 $18.68M -14.0% 2023 $21.71M — Quarterly R&D Expense Quarter Ending R&D Expense YoY QoQ September 30, 2025 $2.18M -42.0% -21.2% June 30, … Read more
Quick Answer ACTUATE THERAPEUTICS, INC. reported Stockholders Equity of $7.92 million for fiscal year 2025. ACTUATE THERAPEUTICS, INC. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $7.92M +7505.6% 2024 $104.2K +100.1% 2023 -$99.63M -32.3% 2022 -$75.31M — Quarterly Stockholders Equity Quarter Ending Stockholders Equity YoY QoQ September 30, 2025 $10.94M +104.1% … Read more
Quick Answer ACTUATE THERAPEUTICS, INC. reported Diluted EPS of $1.06 per share (loss) for fiscal year 2025. ACTUATE THERAPEUTICS, INC. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$1.06 +67.5% 2024 -$3.26 +81.1% 2023 -$17.24 — Quarterly Diluted EPS Quarter Ending Diluted EPS YoY QoQ September 30, 2025 -$0.25 +54.5% +16.7% … Read more
Quick Answer ACTUATE THERAPEUTICS, INC. reported Total Assets of $14.04 million for fiscal year 2025. ACTUATE THERAPEUTICS, INC. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $14.04M +50.6% 2024 $9.32M +211.1% 2023 $3.00M — Quarterly Total Assets Quarter Ending Total Assets YoY QoQ September 30, 2025 $17.71M +24.2% +154.2% June 30, … Read more
Quick Answer ACTUATE THERAPEUTICS, INC. reported Net Income of -$22.23 million for fiscal year 2025. ACTUATE THERAPEUTICS, INC. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$22.23M +18.5% 2024 -$27.29M -10.3% 2023 -$24.74M — Quarterly Net Income Quarter Ending Net Income YoY QoQ September 30, 2025 -$5.41M +9.4% +9.1% June 30, … Read more
Quick Answer ACTUATE THERAPEUTICS, INC. reported Net Income of -$22.23 million for fiscal year 2025. ACTUATE THERAPEUTICS, INC. — Key Financials by Year Metric 2025 2024 2023 2022 Net Income -$22.23M+18.5% -$27.29M-10.3% -$24.74M — Diluted EPS -$1.06+67.5% -$3.26+81.1% -$17.24 — Total Assets $14.04M+50.6% $9.32M+211.1% $3.00M — Stockholders Equity $7.92M+7505.6% $104.2K+100.1% -$99.63M-32.3% -$75.31M R&D Expense $10.29M-44.9% … Read more
Quick Answer ACACIA RESEARCH CORP reported Shares Outstanding of 96.48 million shares for fiscal year 2025. ACACIA RESEARCH CORP Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 96.48M +0.4% 2024 96.05M -3.8% 2024 99.89M -0.0% 2023 99.90M +0.0% 2023 99.89M +129.7% 2022 43.48M -10.9% 2021 48.81M -1.0% 2020 49.28M -2.2% 2019 … Read more
Quick Answer ACACIA RESEARCH CORP reported Operating Income of $6.41 million for fiscal year 2025. ACACIA RESEARCH CORP Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 $6.41M +119.5% 2024 -$32.93M -257.3% 2023 $20.94M +152.2% 2022 -$40.09M -375.6% 2021 $14.54M +174.5% 2020 -$19.52M +16.7% 2019 -$23.42M +5.1% 2018 -$24.69M +9.5% 2017 -$27.27M … Read more
Quick Answer ACACIA RESEARCH CORP reported R&D Expense of $735.0 thousand for fiscal year 2023. ACACIA RESEARCH CORP R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2023 $735.0K +17.4% 2022 $626.0K +213.0% 2021 $200.0K — 2020 $0.00 — Quarterly R&D Expense Quarter Ending R&D Expense YoY QoQ September 30, 2024 $108.0K -37.2% … Read more
Quick Answer ACACIA RESEARCH CORP reported Stockholders Equity of $543.45 million for fiscal year 2025. ACACIA RESEARCH CORP Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $543.45M +5.6% 2024 $514.83M -9.4% 2023 $568.27M +120.0% 2022 $258.28M -38.4% 2021 $419.43M +80.7% 2021 $232.11M +62.1% 2021 $143.20M +15.4% 2021 $124.09M -55.2% 2020 $277.27M … Read more